Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding
about
Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signalingMET: a critical player in tumorigenesis and therapeutic targetCrystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor.A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonistStructural basis for agonism and antagonism of hepatocyte growth factorPAN-modular structure of microneme protein SML-2 from the parasite Sarcocystis muris at 1.95 Å resolution and its complex with 1-thio-β-D-galactoseA novel myocyte-specific gene Midori promotes the differentiation of P19CL6 cells into cardiomyocytesNoncoding mutations of HGF are associated with nonsyndromic hearing loss, DFNB39.Computer-assisted mass spectrometric analysis of naturally occurring and artificially introduced cross-links in proteins and protein complexes.Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor.Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis.Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists.Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis.Protein-protein interactions in receptor activation and intracellular signalling.Docking server for the identification of heparin binding sites on proteins.Heparan sulfate: growth control with a restricted sequence menuStructural basis of hepatocyte growth factor/scatter factor and MET signalling.Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarctionReceptor-tyrosine-kinase-targeted therapies for head and neck cancer.Role of HGF/MET axis in resistance of lung cancer to contemporary management.Differential mitogenic effects of single chain hepatocyte growth factor (HGF)/scatter factor and HGF/NK1 following cleavage by factor Xa.Oligomerization-dependent regulation of motility and morphogenesis by the collagen XVIII NC1/endostatin domainFlexibility and small pockets at protein-protein interfaces: New insights into druggability.Achieving high signal-to-noise in cell regulatory systems: Spatial organization of multiprotein transmembrane assemblies of FGFR and MET receptors.Hepatocyte growth factor/scatter factor binds to small heparin-derived oligosaccharides and stimulates the proliferation of human HaCaT keratinocytes.Preparation of heparin/heparan sulfate oligosaccharides with internal N-unsubstituted glucosamine residues for functional studies.The binding properties of minimal oligosaccharides reveal a common heparan sulfate/dermatan sulfate-binding site in hepatocyte growth factor/scatter factor that can accommodate a wide variety of sulfation patterns.Expression array analysis of the hepatocyte growth factor invasive program.Anomalous inhibition of c-Met by the kinesin inhibitor aurintricarboxylic acid.Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function.Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signaling.Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling.Analogs of the hepatocyte growth factor and macrophage-stimulating protein hinge regions act as Met and Ron dual inhibitors in pancreatic cancer cells.An engineered dimeric fragment of hepatocyte growth factor is a potent c-MET agonist.VEGF(165) requires extracellular matrix components to induce mitogenic effects and migratory response in breast cancer cells.InlB-mediated Listeria monocytogenes internalization requires a balanced phospholipase D activity maintained through phospho-cofilin.Interactions of hepatocyte growth factor/scatter factor with various glycosaminoglycans reveal an important interplay between the presence of iduronate and sulfate density.Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine.H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma.
P2860
Q24296700-5E2E99DC-ECDB-41FF-B2C6-06473556BD1DQ27008925-E51ED8ED-C9DB-4F02-A170-9B04F68F6D7EQ27635335-75F7B33C-9149-4C0F-ACAF-F918CB83CF91Q27647900-B7A93949-00A1-4422-8D5B-5C3A7093C773Q27663368-D6125275-50D3-4266-8C5B-C516498095EEQ27675667-D982C7A0-5BBE-4FFC-BCD6-EF5A0AA68438Q28504765-0A1795DC-CECC-4DB2-8508-B3321F73A31AQ30484106-1CB8880F-CD36-41CA-9CBC-8FCC557FA585Q33231241-DEA07DD6-57B7-4872-9F10-6E988F880660Q33518855-936DE544-B140-434A-A261-D75CE0D5FA9FQ33755200-58839057-9167-4629-8B50-FDAE3066AAB3Q33786959-9BEC0DA7-E55F-40A2-9A5D-738EF98ED144Q33970874-5F56339B-92DF-4BEE-A7B1-92539DA4C6D4Q34068511-5C01C380-B4D5-452D-862B-A9BDC61059FCQ34081480-E82D6C00-4FDB-47C2-8C8B-873BBF2AD089Q34285002-2E820134-5E99-4F14-9432-EDC8FC740EDAQ34328757-FD2458BF-7A45-46FF-BB87-3D42B984B642Q34572895-692B5F6C-A23B-4DEA-98AF-6A33C81C150FQ35078379-F61F0E8B-2E11-45F0-9115-093DC5C079F7Q35102025-D0EFD11D-B084-4361-ABA6-849EA92297E4Q35200337-25F26CB2-A7B8-4A70-9B9D-D6C24D780336Q35677691-6E2077DE-37FA-46F8-8F21-6C0A2BDBB44CQ36381104-F0D20095-A436-482C-A6CF-B4E6B74913D6Q36501662-04A11521-DE5E-49DB-A171-67A8BAA24A71Q36798972-9B516B97-258A-469A-9DBE-08533DF391A7Q38292865-B4C7F6B2-0398-4CB4-A841-75853EAF7241Q38331584-E419E9F2-4FEB-41DF-9313-1EE7F552E655Q38357819-43CCA12A-62B2-4D8E-B66F-B6EA69B6ECCAQ38847534-D644151C-54BF-4B89-9876-67DA540B5600Q39576693-F6D80524-DFDA-485B-99FD-FD0D49E010C2Q40552063-6052D750-69E2-4750-8F5C-085A80662283Q40795221-B951235D-4C95-4A59-B107-F9EB04860D11Q41131252-5F8FB9B5-901C-4332-B8FB-0ED2DB9DA31FQ41205527-96E1D807-0798-4AA1-96F4-C0080729C84AQ42088207-F9B2B708-CA92-4157-8DD0-E7B29E3F93B9Q43747243-46F3D577-2632-471D-965D-EE4A3FC93C5FQ44056045-4D8E6D90-4765-43A4-BCCF-46854D3DF880Q46835307-C6C72383-3931-4334-BB44-C619D4AFC4A6Q49491161-6010883A-CCCD-4D9A-AD1C-6D96571D31C6Q49952146-B88AF586-4F62-44F6-886C-8188EC2E53B3
P2860
Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Crystal structure of the NK1 f ...... erization and receptor binding
@ast
Crystal structure of the NK1 f ...... erization and receptor binding
@en
Crystal structure of the NK1 f ...... erization and receptor binding
@nl
type
label
Crystal structure of the NK1 f ...... erization and receptor binding
@ast
Crystal structure of the NK1 f ...... erization and receptor binding
@en
Crystal structure of the NK1 f ...... erization and receptor binding
@nl
prefLabel
Crystal structure of the NK1 f ...... erization and receptor binding
@ast
Crystal structure of the NK1 f ...... erization and receptor binding
@en
Crystal structure of the NK1 f ...... erization and receptor binding
@nl
P2093
P356
P1476
Crystal structure of the NK1 f ...... erization and receptor binding
@en
P2093
P356
10.1038/4947
P50
P577
1999-01-01T00:00:00Z